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Abstract
Metabolic traits are molecular phenotypes that can drive clinical phenotypes and may predict disease progression. Here, we
report results from a metabolome- and genome-wide association study on 1H-NMR urine metabolic profiles. The study was
conducted within an untargeted approach, employing a novel method for compound identification. From our discovery
cohort of 835 Caucasian individuals who participated in the CoLaus study, we identified 139 suggestively significant
(P,561028) and independent associations between single nucleotide polymorphisms (SNP) and metabolome features.
Fifty-six of these associations replicated in the TasteSensomics cohort, comprising 601 individuals from Sa˜o Paulo of vastly
diverse ethnic background. They correspond to eleven gene-metabolite associations, six of which had been previously
identified in the urine metabolome and three in the serum metabolome. Our key novel findings are the associations of two
SNPs with NMR spectral signatures pointing to fucose (rs492602, P= 6.9610244) and lysine (rs8101881, P= 1.2610233),
respectively. Fine-mapping of the first locus pinpointed the FUT2 gene, which encodes a fucosyltransferase enzyme and has
previously been associated with Crohn’s disease. This implicates fucose as a potential prognostic disease marker, for which
there is already published evidence from a mouse model. The second SNP lies within the SLC7A9 gene, rare mutations of
which have been linked to severe kidney damage. The replication of previous associations and our new discoveries
demonstrate the potential of untargeted metabolomics GWAS to robustly identify molecular disease markers.
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Introduction
Genome-wide association studies (GWAS) search for associa-
tions between phenotypes and common variants within large
collections of samples [1]. These studies usually focus on
organismal phenotypes [2–6]. Recently however, molecular
phenotypes, including gene-expression [7,8] and metabotypes
[9–14], have also been investigated. Studying the effects of genetic
variations on molecular phenotypes is motivated by two charac-
teristics common to the vast majority of GWAS on organismal
phenotypes: first, the biological mechanisms underlying the
associations are often unknown; and second, the significantly
associated loci individually explain only a small fraction of
variability of the organismal phenotype, and even cumulatively
fall far from explaining the estimated heritability of the phenotype
[15]. Molecular phenotypes can be considered as far less removed
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from the primary causal variants. In agreement with this, GWAS
on these phenotypes uncover associations generally characterized
by larger effect sizes and higher explained variances. For example,
the study of gene expression data from different tissues revealed
hundreds of SNPs explaining a significant portion (.5%) of the
gene expression levels of (usually) neighboring genes. These
expression quantitative trait loci (eQTL) overlaid with GWAS hits for
organismal phenotypes reveal significant enrichment [16], hinting
at the underlying causal biological mechanisms. Large effect sizes
have also been observed for many metabolic quantitative trait loci
(mQTL) (see [17] for a recent review). Indeed, several metabolite
concentrations measured in urine or serum are genetically
determined in a close-to-monogenic manner [10,12,18]. More
recently, mQTLs have been studied in more depth in the context
of organismal phenotypes in order to develop potential prognostic
disease markers [11,19].
The technologies used to measure the metabolome (gen-
erally mass spectrometry or NMR spectroscopy) produce high-
dimensional raw data. Most GWAS for mQTLs employ estimates
of metabolite concentrations that have been derived from these
data after normalization. This data transformation is far from
trivial, and is performed only for a subset of at most a few
hundred metabolites of the much larger set of known human
metabolites. The non-transformed data are ignored in the
subsequent GWAS, so that this targeted approach to mQTL
GWAS discards potentially valuable raw data captured by the
analytical technique. In our study, we followed an untargeted
approach, similar to the one previously used in the analysis of
rodent [20,21] and human metabolism [22]. In this approach,
instead of seeking to transform normalized data into metabolite
concentrations as target traits for GWAS, we use the normalized
data themselves as phenotypes to be associated with the
genotypes, thereby pinpointing metabolome features from these
data that have a genetic association. The subsequent identifica-
tion of metabolites is attempted only using these features, and
thereby focused on compounds whose concentrations have a
significant genetic determinant.
Results
Our study concerns metabolites in urine samples, measured by
1H-NMR spectroscopy (details on sample preparation and
spectrum acquisition are provided in the Materials and Methods
section). We binned the 1H-NMR spectra into approximately
2,000 uniform bins, and defined the average intensity of the NMR
signal in a bin as a metabolome feature. In our untargeted approach,
we used these features—which, combined, contain the full
spectroscopic data—as molecular phenotypes. After quality
filtering (Materials and Methods), we maintained 1,276 of these
features for subsequent analysis. We then followed a two-stage
GWAS design, wherein we tested all possible SNP-feature pairs for
association in the Cohorte Lausannoise, or CoLaus (see figure 1A for
the Manhattan plot corresponding to a single feature, figure S1 for
a three-dimensional illustration of Manhattan plots for all features,
and figure 1B for the P-value heat map summarizing only the
significant associations). After pruning according to SNP linkage
and feature correlation, pairs indicating suggestively significant
association (P-value below 561028) in CoLaus (N= 835) were
tested for replication in the TasteSensomics cohort [23,24] (N= 601).
Out of 139 discovered independent associations, 56 replicated (see
table S1 for detailed list).
For this manageable set of reproducible associations, we then
sought to identify the underlying metabolites. To this end, we
devised a method that we call metabomatching. Our method makes
use of the fact that the NMR spectrum of most metabolites
comprises multiple peaks, so that the genetic effect of a SNP on a
metabolite usually results in associations of that SNP with multiple
metabolome features. This concept is best visualized by way of the
pseudo-spectrum of a SNP (see figure 1C for an example), consisting
of the set of significance values (2log(P-values)) of its associations
with each of the 1,276 features. We observed that in cases where
the genetic effect is sufficiently strong, the pseudo-spectrum tends
to be similar to the NMR spectrum of the underlying metabolite,
allowing its identification.
Specifically, for a given SNP, metabomatching assigns scores to
all metabolites with known NMR spectrum. The scores are
computed using the significance values of the features that
correspond to peaks in the known spectra (see Materials and
Methods for details). The metabolites are then ranked, based on
these scores, to identify the candidate metabolites most likely to
underlie the association. As an example, for SNP rs37369, the top-
ranked candidate metabolite is 3-aminoisobutyrate, thereby
replicating the association found in previous metabolomics studies
[11,12,22]. Figure 2A shows how closely the NMR spectrum of 3-
aminoisobutyrate (upper half) matches the pseudo-spectrum of
rs37369 (lower half).
In order to evaluate the robustness of the metabomatching
method, we collected all known metabolites whose concentrations
in urine had previously been found to be associated with SNPs by
the two largest-to-date studies [12,22]. Among these established
SNP-metabolite pairs, we then considered only those for which
our association P-values are below 1026 and whose metabolites
have a known NMR spectrum (see table S2). For these controls,
metabomatching proved very efficient in selecting the reference
compounds, which ranked within the top 1% for 5 out of 7 testable
associations, and within the top 10% for the remaining two (see
figure 2A–C and figure S2). Encouraged by these findings, we
decided to use metabomatching to identify the metabolites (or
metabolite families) underlying some of our associations.
Grouping features by metabolites and SNPs by genetic loci, we
reduced our 56 SNP-feature associations to 11 locus-metabolite
associations, listed in table 1. We replicated the previously
Author Summary
The concentrations of small molecules known as metab-
olites, are subject to tight regulation in all organisms.
Collectively, the metabolite concentrations make up the
metabolome, which differs amongst individuals as a
function of their environment and genetic makeup. In
our study, we have further developed an untargeted
approach to identify genetic factors affecting human
metabolism. In this approach, we first identify all genetic
variants that correlate with any of the measured metabo-
lome features in a large set of individuals. For these
variants, we then compute a profile of significance for
association with all features, generating a signature that
facilitates the expert or computational identification of the
metabolite whose concentration is most likely affected by
the genetic variant at hand. Our study replicated many of
the previously reported genetically driven variations in
human metabolism and revealed two new striking
examples of genetic variations with a sizeable effect on
the urine metabolome. Interestingly, in these two gene-
metabolite pairs both the gene and the affected metab-
olite are related to human diseases – Crohn’s disease in the
first case, and kidney disease in the second. This highlights
the connection between genetic predispositions, affected
metabolites, and human health.
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published urine associations of ALMS1 with N-acetylated com-
pounds (figure S2A), AGXT2 with 3-aminoisobutyrate (figure 2A),
and PSMD9 with 2-hydroxyisobutyrate (figure S2D). For PYR-
OXD2, we replicated the association with trimethylamine
(figure 2B), but also found associations with several features not
part of the spectrum of trimethylamine, suggesting that one or
more additional metabolites could be implicated. Similarly, the
published association of NAT2 is with the formate-succinate ratio
[12], but neither of these compounds contains the features
implicated by our association (Figure S2C). For the associations
of SNPs in ACADL, ABO, and ACADS, linked SNPs have been
found to associate with metabolite concentrations in serum.
However, without conclusive identification of the metabolites
underlying the associated features we could not determine whether
our associations are the exact urine analogs of known serum
associations, or whether they involve novel or related metabolites.
In the traditionally applied SNP-pruning procedure, focus is
given only to the most significant SNP and the phenomenon of
(semi-)independent contribution of adjacent SNPs (termed as allelic
heterogeneity) is ignored. To overcome this limitation, we tested for
allelic heterogeneity for each of our 11 locus-feature pairs using
multivariate association [25,26]. We found evidence for secondary
signals for four of these pairs in the CoLaus sample, and for two of
them, both involving the AGXT2 locus, allelic heterogeneity was
replicated in the TasteSensomics cohort (table 2). For these
replicating cases, the variance explained by the multiple SNP
association was up to 50% greater than that of the single SNP
association, demonstrating the importance of allelic heterogeneity,
still often overlooked in GWAS [26].
For our first novel association, metabomatching allowed the
identification of the underlying metabolite. As illustrated in
figure 2D, the pseudo-spectrum of rs281408 (lower half) closely
resembles the NMR spectrum (upper half) of the top-ranked
candidate, fucose. We confirmed this in-silico identification using
NMR spectroscopy of fucose-spiked urine samples. In CoLaus, the
SNPs associated with fucose fall within a large LD block on
chromosome 19 encompassing the FUT2, RASIP1, and IZUMO1
genes. However, the TasteSensomics population has a different
genetic structure within this region (figure S3), such that the
combined association signal, led by rs492602 (r2=0.87 with
rs281408), could be narrowed down to FUT2 specifically
(Figure 3A). FUT2 encodes a fucosyltransferase enzyme that is
essential for the secretion and display of ABO blood group
antigens on mucosal surface cells. Mucosal ABO-antigens serve as
attachment points for both beneficial gut bacteria and harmful
viruses [27,28], which is thought to have driven the complex
evolution of FUT2 [29]. In addition, fucose, the substrate of the
fucosyltransferase enzyme, was shown to impact human gut
Figure 1. Genome- and metabolome-wide analysis results, first stage. (A) Manhattan plot for feature 1.2025. (B) Genome- and metabolome-
wide P-value heat map, showing associations with PC,5610
28 in CoLaus. (C) Pseudo-spectrum for SNP rs37369, obtained by plotting the association
P-values between rs37369 and all metabolic features.
doi:10.1371/journal.pgen.1004132.g001
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microbial composition [30,31], and thereby gut health [32,33].
The role of FUT2 in gut microbial ecology is further substantiated
by the association of its SNP rs281379 (r2=0.76 with rs492602)
with Crohn’s disease (CD), as found in a sample of over 50 K
individuals [34] (figure 4A). Several urinary metabolites (not
including fucose) were shown to distinguish between inflammatory
bowel disease patients (including those with CD) and healthy
subjects [35]. Moreover, significantly elevated fucose levels in
urine were found in mice with an interleukin-10 deficiency, the
mouse model of CD [36,37]. This FUT2-independent link
between urinary fucose levels and CD may be indicating that
the elevated urine fucose levels, also observed in human FUT2
non-secretors, do not simply result from the elimination of fucose
that was not secreted into the mucosal layers. Instead this elevation
may be a consequence of (and metabolic indicator for) early sub-
symptomatic changes from a healthy gut flora towards the
dysbiosis of CD. While its exact role is unclear, fucose is certainly
an interesting candidate for further exploration of the metabolic
causes and effects of CD, or inflammatory bowel disorders in
general.
Our second novel association links the SNP rs8101881 with a
metabolite identified as lysine by our metabomatching method
(figure 2C). This SNP falls within the SLC7A9 gene (in a different
region of chromosome 19, see Figure 3B). SNPs at this locus have
already been found to be significantly associated with the lysine/
valine ratio [12], but not lysine alone. SLC7A9 is linked to kidney
function: rare mutations in SLC7A9 cause severe kidney damage
[38], and a common variant (rs12460876, linked to rs8101881
with r2=0.996) is associated with the estimated glomerular
filtration rate (eGFR) [39], which is a key clinical measure of
kidney health. Interestingly, lysine concentration shows a strong
association with eGFR in the combined CoLaus and TasteSensomics
sample (xm=0.038, SE= 0.008, Pm=8.1610
27), regardless of the
rs8101881 genotype. To further explore these links (figure 4B) we
used Mendelian randomization (MR) [40,41] in order to assess
whether lysine levels may be causative for chronic kidney disease.
We employed rs8101881 as instrument (F-statistic = 46.22) and the
tests proposed by Glymour et al. [42] indicated no violation of the
assumptions of MR. We then computed the two-stage least-
squares (2SLS) estimate as done by Ehret et al. [2], where the
rs8101881-lysine effect was calculated combining the results from
the CoLaus and TasteSensomics cohorts, while the effect of rs8101881
on eGFR was estimated using CKDGen [39] summary statistics.
Although the 2SLS estimate was consistent (overlapping in
confidence interval) with the ordinary least-squares (OLS) estimate
of lysine on eGFR (xm=0.038), it was non-significant (x=0.02,
P=0.54), hence we have no sufficient evidence to claim a causal
effect of lysine levels on eGFR.
Discussion
We conducted a genome- and metabolome-wide association
study of untargeted NMR data to reveal novel SNP-feature
associations. Using both manual and automated annotation, we
identified the metabolites underlying more than half of the
discovered associations.
The high number of associations found to replicate (56 out of
139) is indicative of the robustness of mQTL GWAS in general,
and our feature-based approach in particular. Our discovery and
replication cohorts have different population origins —European
for the Swiss cohort CoLaus, genetically admixed, from African,
European, and Asian founders, for the Brazilian cohort TasteSen-
somics—indicating that the genetic effects on the metabotypes are
likely to be both ethnicity-independent, and robust against
potential variations of diet and other environmental factors.
The two metabolomic data sets we used for discovery and
replication were collected independently, initially without the
intention of combining them. As a result, the respective
Figure 2. Metabomatching. Each subfigure compares the CoLaus pseudo-spectrum (bottom half) with the NMR spectrum (top half) of the most
likely candidate for the associated metabolite. (A) rs37369 vs. 3-aminoisobutyrate. (B) rs2147896 in PYROXD2 vs. trimethylamine (C) rs8101881 in
SLC7A9 vs. lysine (D) rs281408 in FUT2 vs. fucose.
doi:10.1371/journal.pgen.1004132.g002
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experimental conditions were not always well matched (see
Materials and Methods for details). Since differences in the
experimental setups can cause significant changes in the chemical
shifts of specific metabolite absorption bands, one could have
expected that this would cause a significant problem to our
feature-based approach. Yet in practice, this did not appear to be a
significant impediment, given the high rate of replication between
our two studies. This indicates that the feature-based approach is
rather robust against variations in experimental conditions. The
reliability of the feature-based approach is further evidenced by
the high overlap between our associations and previously
described results [11,12,22].
In comparison to previous targeted approaches, where metab-
olite identification is applied before GWAS, the feature-based
approach has two main advantages. The first, and most important
one, is that by moving the identification of metabolite concentra-
tions after the association phase, the complete metabolomic data
captured by spectroscopy are analyzed. As a consequence, the
feature-based approach can potentially provide additional associ-
ation signals that would have been missed by a targeted approach.
The second advantage, which is of a more pragmatic nature, is
that the burden associated with metabolic identification is
considerably reduced. Indeed only the metabolites of interest,
namely those found to have a genetic component, need
identification. Even so, identification of all metabolites of interest
can prove difficult, and cases may exist where identification will
require further experimental work (like the collection of two-
dimensional homo- and heteronuclear NMR spectra, for exam-
ple). Such additional analysis was precluded in our study due to
the destruction of samples after 1H-NMR analysis in accordance
with study protocols and informed consent.
A key message of our study is that our metabomatching method
may be useful for other cohort-based metabolomics projects when
resources for compound identification in terms of material or
expert time are limited. Essentially, the information inherent in the
GWAS signals can complement (and sometimes even replace)
traditional sample-based metabolite identification. As the infor-
mation in databases of NMR spectra of individual metabolites
increases, the method may become a powerful strategy for
metabolite identification in GWAS involving untargeted metabo-
lomics.
In summary, the replication of locus-metabolite associations
with previous studies [9–13] and the unequivocal identification of
two new gene-metabolite associations indicate that the feature-
based approach, combined with pseudo-spectrum based identifi-
cation, is a reliable approach for metabolome- and genome-wide
Table 2. Allelic heterogeneity at the AGXT2 locus.
Locus CoLaus TasteSensomics
Chr Position Feature SNP PC xC R
2 R2diff model P Feature SNP PT xT R
2 R2diff model P
5 34,537,671–
35,578,717
1.2025 rs37370 2.1610237 0.95 0.278 0.079 2.061024 1.204 rs37370 2.2610221 0.92 0.130 0.047 2.061024
rs7717823 1.1610220 20.47 rs455423 5.961028 20.41
rs6880595 5.161024 0.18
5 34,537,671–
35,578,717
3.0975 rs37369 3.6610216 0.78 0.115 0.023 2.261023 3.096 rs37370 6.6610212 0.68 0.097 0.026 6.261023
rs7717823 3.561026 20.25 rs455423 1.061024 20.31
Abbreviations: PC, PT – P-values, xC, xT – multivariate effect sizes, R
2 – explained variance of full model, R2diff – additional explained variance of full model compared to
best single SNP association, model P – probability of observing same or equal R2diff increase with the same stepwise model selection for 2,500 permuted phenotypes.
doi:10.1371/journal.pgen.1004132.t002
Figure 3. Local Manhattan plots. The Manhattan plots show combined 2log(P-values) in the neighborhood of the most strongly associated SNP
for (A) the FUT2 with fucose association, and (B) the SLC7A9 with lysine association.
doi:10.1371/journal.pgen.1004132.g003
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association studies. In cases where newly identified association
signals are of marginal strength, metabolite identification may be
followed-up by model-based quantification of the metabolite
[43,44] to potentially improve the association signal, and provide
a more accurate effect size estimate. While the assignment to
metabolites of all associated features can require substantial
follow-up work, this may not be necessary if the primary objective
of a study was to elucidate novel genetic loci relevant for general
metabolomic variability. Specifically, while associations with
unidentified metabolites may lack a direct mechanistic interpre-
tation, they can still prove to be valuable biomarkers of certain
clinical phenotypes [45,46]. Finally, the unidentified metabolite
underlying an association may correspond to an unknown metabolite
in the sense, used in Krumsiek et al. [47], of ‘‘a molecule which can
reproducibly be detected and quantified […] but whose chemical
identity has not been elucidated’’, in which case the genetic
association itself may provide identifying information.
Our GWAS revealed two new SNP-metabolite associations of
potential clinical relevance. We found urine fucose concentration
to be associated with variants in the FUT2 gene, which is linked to
gut microbial ecology in general, and to Crohn’s disease in
particular. Furthermore, we found urine lysine concentration to be
associated with SNPs in the SLC7A9 gene, which is linked to
kidney function and to kidney failure specifically. We confirmed
the link to kidney function with a significant lysine-eGFR
association. Our Mendelian randomization was inconclusive for
a causal link between urine lysine levels and eGFR (as a measure
of kidney filtering capacity). Yet, we only had about 12% power
and a sample size of at least 11,400 would be required for
providing a conclusive answer (i.e. having over 80% power).
Molecular trait association can not only help us to better
understand the underlying biological processes, but also shed light
on the interplay between genetic predisposition and environmental
factors. In our case, figuring out how lysine levels are influenced by
diet may thus help to develop nutritional intervention programs to
counter kidney problems before they manifest themselves in a
clinical phenotype. In summary, this study provided specific
evidence that genetically influenced metabolite concentrations can
play a crucial role in disease progression, and that these
metabolites may provide an avenue for better diagnosis and
prevention of diseases.
Materials and Methods
For the Cohorte Lausannoise (CoLaus) study, genotyping was
performed using the Affymetrix GeneChip Human Mapping
500 K array set. Genotypes were called using BRLMM [48].
Duplicate individuals, and first and second degree relatives, were
identified by computing genomic identity-by-descent coefficients,
using PLINK [49]. The younger individual from each duplicate or
relative pair was removed. Individuals with call rate below 90%
were excluded from further analysis. The full set of unmeasured
HapMap II SNPs (release 21) was imputed using 390,631
measured SNPs (with Hardy-Weinberg P-value above 1027 and
MAF above 1%). Imputation was performed using IMPUTE [50]
version 0.2.0. Expected allele dosages were computed for
2,557,249 SNPs.
For the TasteSensomics study, genotyping was performed on the
Illumina Human Omni-Quad1 platform. Genotype calling was
performed with Beadstudio software (Illumina). Calls with a
genotyping score below 0.2 were excluded from further analysis.
SNPs with a call rate below 90% and individuals with a call rate
below 95% were also excluded, leaving 989,972 available SNPs,
with an overlap of 713,870 SNPs with the CoLaus cohort. No
imputation was performed in this cohort, since none of the
available HapMap panels were considered as sufficiently repre-
sentative for the admixed population investigated in this study.
In the CoLaus cohort, 974 individuals each provided 1 urine
sample for metabolic analysis. The CoLaus study was approved by
the Institutional Ethics Committee of the University of Lausanne.
All study participants gave written consent including for genetic
studies. Prior to urinalysis, samples were stored at 280uC. Each
sample was comprised of 400 mL urine and 200 mL of a 0.2M
deuterated phosphate buffer solution (pH 7.4). Samples were
centrifuged to remove precipitates, and to 500 mL aliquots of the
resulting supernatant, 100 mL of a solution of 0.1% (w/v) sodium
trimethylsilyl propionate (TSP) and 1% (w/v) sodium azide in
D2O was added. The TSP provided a chemical shift reference
(d0.0), the sodium azide acted as a bactericide, and the D2O
provided a deuterium field-frequency lock signal for the NMR
spectrometer. 1H NMR spectra were acquired at 300 K on a
Bruker Avance II 700 MHz spectrometer (Bruker Biospin,
Rheinstetten, Germany) using a standard 1H detection pulse
sequence with water suppression.
In the TasteSensomics cohort, 601 individuals donated 3 samples
each over a period of 2 weeks. 3 mM sodium azide was added to
the samples to prevent microbial growth. Samples were then
frozen and stored at 280uC prior to urinalysis. Urine aliquots of
400 mL were adjusted to pH 6.8 using 200 mL of deuterated
phosphate buffer solution (final concentration of 0.2M) containing
1 mM of sodium TSP. 1H NMR spectra were recorded at 300 K
on a Bruker Avance II 600 MHz spectrometer, using a standard
1H detection pulse sequence with water suppression.
CoLaus 1H spectra were binned in chemical shift increments of
0.005 ppm, resulting in metabolic profiles of 2,200 metabolome
features. Filtering out features then samples with more than 5% of
missing values, a dataset composed of 1,276 features for 835
individuals was obtained. TasteSensomics 1H spectra were binned in
increments of 0.0032 ppm, resulting in profiles of 2,400 features.
Figure 4. Genotype-Metabotype-Phenotype associations. The
two novel gene-metabolite associations of this study implicate SNPs
that had previously been associated with disease-related phenotypes
by the indicated publications: (A) Fucose–Crohn’s disease–FUT2
(rs492602), (B) Lysine–eGFR–SLC7A9 (rs8101881). A link between the
metabolite and the phenotype has been established for (A) based on a
mouse model and for (B) by a direct correlation with the indicated
significance and effect size. Abbreviations: OR refers to the odds ratio, x
to the linear regression effect size, P to the corresponding P-value, and
the m-index indicates values obtained in the combined CoLaus and
TasteSensomics sample.
doi:10.1371/journal.pgen.1004132.g004
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More sophisticated binning procedures, such as adaptive binning
[51,52], could have been applied, but standard uniform binning
has been shown to be successful by us [53,54] and others [55,56].
Bin intensities were log-averaged across replicate samples for each
individual, and spectral qualities were such that all features and
subjects were included in the analysis. For each individual, we
applied a Z-score transformation in order to achieve zero mean
and unit variance. This statistical normalization yields metabolic
profiles similar to those resulting from common biological
normalizations, such as normalization by total metabolite content
(median correlation r=0.92), or normalization by urinary
creatinine measured before freezing and thawing (resulting in
lower median correlation r=0.45).
In addition to the standard confounding factors that are age,
sex, post-menopausal status, and the principal components of the
genotype, metabolic profiles are sensitive to lifestyle factors, dietary
behavior, and creatinine levels. Among the 36 such factors
available for the CoLaus sample, we select those which associated
with at least 2% of the features, resulting in the 12 factor subset
comprising age, sex, post-menopausal status, the 1st principal
component of the genotype, the 2nd and 4th principal components
of the dietary profile, smoking behavior, caffeine intake, alcohol
intake, physical activity, urinary creatinine, and serum creatinine.
For every feature, we use as covariates those factors which, in a
stepwise method, significantly associate (P,0.05/12) with the
feature. For the TasteSensomics feature, covariates were similarly
selected (P,0.05/5) among the factors age, sex, BMI, and the first
two principal components of the genotype.
We tested the 1,276 features for association in the CoLaus cohort
with the 713,870 SNPs also measured in the TasteSensomics cohort.
We pruned the suggestively significant (P,561028) SNP-feature
association pairs by considering two pairs equivalent if their SNPs
were in LD (r2.0.3) and their features were correlated (r2.0.4).
This procedure is an extension of the clumping method
implemented in PLINK [49]. We then sought replication in the
TasteSensomics cohort [23,24]. Replication was declared if the
discovery and replication effect directions were concordant, the
replication P-value was below 0.05/#hits, and the combined
association P-value below 5.7610210. The latter P-value threshold
corresponds to the Bonferroni multiple testing correction for both
features, where the effective number of tests was estimated [57] to
be 125, and SNPs.
To use the admixed genetic background of the TasteSensomics
cohort for narrowing down the genetic loci giving rise to the
association signals, we grouped the replicating SNP-feature
associations by genetic loci (1 Mb neighborhood), and ran
associations between the implicated feature(s) with all available
SNPs in both (discovery and replication) cohorts at the locus. We
then meta-analyzed the local association summary statistics (see
table S3). The combined results for the strongest association at
each locus are reported in table 1.
Features do not directly correspond to the concentration of a
single metabolite, so that feature ratios are difficult to interpret.
Therefore, in contrast to previous metabolomics association
studies, we do not include feature ratios in the first association
phase, which substantially reduced the multiple testing burden.
The features involved in replicated associations were subjected
to both manual and automated metabolite annotation. Manual
annotation was performed using in-house libraries, reference
spectra from public databases (HMDB http://www.hmdb.ca,
BMRB http://www.bmrb.wisc.edu, Prime http://prime.psc.
riken.jp), and the Chenomx NMR Suite software, version 7.1
(Chenomx Inc, Alberta, Canada). Automated annotation was
performed by our metabomatching method (http://www.unil.ch/
cbg), which compares the pseudo-spectrum (see main text) to the
spectrum of all metabolites for which a reference spectrum is
available in HMDB (to date around 850 metabolites). After
pruning correlated spectral bins (to ensure independence) we
quantified the similarity between the pseudo-spectrum and the
spectrum of a given metabolite by summing up the squared
association test statistics
X
i~1
k xi
SEi
 2
corresponding to the k (independent) peaks present in the spectrum
of the metabolite. The resulting test-statistic is x2-distributed with k
degrees of freedom. This allows for obtaining a P-value for having
observed as good a match between the pseudo-spectrum and the
NMR spectrum as by chance. The procedure is repeated for all
metabolites in HMDB, which are then ranked according to their
P-values.
For each SNP with confirmed metabolite association, we
examined the surrounding 1 Mb window searching for evidence
of allelic heterogeneity or imperfect tagging. Within each 1 Mb
region, we looked for the best multivariate model (in the sense of
AIC) to explain the corresponding metabolic feature in the CoLaus
sample. If this model provides a significantly better fit to the data
than the lead SNP, we attempted to replicate in the TasteSensomics
cohort. Note that due to the different LD structure in the CoLaus
and TasteSensomics cohorts we did not attempt to replicate the exact
same SNPs, but the locus. In case of successful replication we
declare the locus to exhibit multiple independent signals. We also
attempted fine-mapping of association signals in these regions,
using 1000 Genomes imputed genotype association, but no
stronger association was revealed.
Mendelian randomization (MR) was carried out by calculating
two-stage least squares estimates and comparing them to the direct
one stage effect size. We used an SLC7A9 SNP (rs8101881) as
instrument to infer causality between lysine concentration and log
transformed age- and sex-corrected eGFR. To verify the
assumptions of MR, we noted that the instrument was strongly
associated with lysine and, since it is a genotype, is very unlikely to
have a common cause with eGFR. The final assumption of MR,
namely that all causal effect of the SNP on eGFR is acting through
lysine, was examined by verifying that our variables satisfied all of
the tests of positive unmeasured confounding (leveraging prior
casual assumptions) proposed by Glymour et al. [42]. The selected
SNP was not found to be associated with any known confounding
factors of eGFR. We used the Durbin-Hausman test [58] to
compare the OLS and the 2SLS estimates.
Supporting Information
Figure S1 Metabolome- and genome-wide association P-values
in CoLaus. Significant associations (PC,10
28/125) involving
features deriving from identified metabolites are shown in color.
The carbon-atoms carrying the protons corresponding to the
significantly associated features are labeled in the chemical
structures.
(PDF)
Figure S2 Additional metabomatching results. Each subfigure
shows: (upper half) the NMR spectrum of the control metabolite,
and (lower half) the pseudo-spectrum of the CoLaus SNPs (linked to
the control SNP) with the strongest association to a feature
corresponding to one of the peaks of the control metabolite NMR
spectrum. (A) N-acetyl-L-lysine: top ranked member of the N-
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acetylated compound family, vs. rs6546847 in ALMS1; (B)
Dimethylglycine vs. rs17279437 in SLC6A20: while the association
of rs17279437 with feature 2.9325 satisfies the threshold for
significance in CoLaus, the association does not replicate in
TasteSensomics; (C) Top-ranked compound pair in two-compound
metabomatching involving formate, vs. rs4921914 in NAT2:
rs4921914 is only associated significantly with features which do
not correspond to the single peak in the NMR spectrum of
formate; (D) 2-hydroxyisobutyrate vs. rs7314056 in PSMD9. The
metabomatching results for 3-aminoisobutyrate, trimethylamine,
lysine, and fucose are shown in the main text.
(PDF)
Figure S3 LD structure in the FUT2, RASIP1 and IZUMO1
region on chromosome 19. For CoLaus (lower triangle), the LD
block from rs516246 (ad) to rs11667321 (bh) is associated with
fucose, with the strongest association for SNP rs281408 in RASIP1.
For TasteSensomics, the much smaller LD block from rs516246 (ad)
to rs633372 (am) is associated with fucose, with the strongest
association for SNP rs492602 (ae). The combined association
signal mirrors the TasteSensomics signal, with again SNP rs492602
showing the strongest association.
(PDF)
Table S1 Details of the 56 SNP-feature associations for which: (1)
the discovery P-value, PC, was below 5610
28, (2) the replication P-
value, PT, was below 0.05/139 (139 associations were found in
discovery), (3) the effects matched directions, (4) and the combined
P-value obtained by meta-analysis, Pm, was below the Bonferonni
threshold of 561028/125. Positions are listed according to NCBI
build 36; MAF is the minor (effect) allele frequency.
(PDF)
Table S2 Metabomatching testing control SNP-metabolite
pairs, and ranking results. Metabomatching tends to perform
better in cases involving multi-peak spectra. Control pairs
correspond to associations previously discovered in urine metabo-
lome GWAS (from Nat Genet, 2011. 43(6): 565–9 and PLoS Genet,
2011. 7(9): e1002270), such that: (1) the metabolite is not a ratio;
(2) the control association P-value, Pref, is below 5610
28 (3) the
metabolite has a known NMR spectrum; (4) there exists, in CoLaus,
an association between a (linked) SNP and a feature corresponding
to a peak of the control metabolite NMR spectrum with
association P-value, PC, below 10
26.
(PDF)
Table S3 Association signal meta-analysis. Association signal
meta-analysis. For each locus-metabolite association, the lead
SNPs for CoLaus, TasteSensomics, the cohorts combined, and cohorts
from previous studies, are listed, unless the lead SNP is consistent
across the four. The published lead SNPs for N-acetylated
compounds (rs9309473 in MolPAGE), as well as those for
trimethylamine (rs7072216 in MolPAGE) and 2-hydroxyisobuty-
rate (rs830124 in SHIP) are not part of either the CoLaus nor
TasteSensomics panels but are in perfect LD (r2 =D’=1, HapMap
Rel 22) with the CoLaus lead SNPs rs6546847, rs2147896, and
rs7314056, respectively. We therefore consider them equivalent
for the purpose of this table. As a result, the trimethylamine and 2-
hydroxyisobutyrate associations have a consistent lead SNP and
are not listed. Positions are listed according to NBCI build 36.
Stars in the Lead in C; T; m; P columns indicate whether the SNP is
the lead SNP in the respective cohort; a dash in the Lead in P
column indicates there is no previously published association, in
urine. P_ and x_ are the P-values and effect sizes for the SNP in
CoLaus, TasteSensomics, and the cohorts combined, respectively. rC
2
measures the linkage disequilibrium computed with the CoLaus
genotype between the SNP and the CoLaus lead SNP. rT
2 measures
the linkage disequilibrium computed with the TasteSensomics
genotype between the SNP and the TasteSensomics lead SNP. For
AGXT2, the combined lead SNP is not the shared lead SNP. This
can result from the inverse-variance weighting meta-analysis
(which assumes common effect sizes) when the associations have
different effect sizes across cohorts, as is the case for rs37369. This
effect size difference can stem from the differing minor allele
frequencies, of 0.08 in CoLaus and 0.29 in TasteSensomics. The
ALMS1 locus is a good example for how admixed populations can
narrow the association signal. While the causal SNP is most
probably shared in the two cohorts, a SNP in LD has taken lead of
the association signal in CoLaus due to stochastic fluctuations or
because the causal SNP in unmeasured. This CoLaus proxy may
not be a proxy in the TasteSensomics cohort due to the different LD
structures. The meta-analysis attenuates the association signal for
this type of SNPs, thereby producing a cleaner signal comprising
only SNPs in LD with the causal SNP in both cohorts.
(PDF)
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